The effects of a new ultra-short-acting β-adrenergic blocker, ONO- 1101, on cardiac function during and after cardiopulmonary bypass

被引：0

作者：

Ahmet I. ^{[1
]}

Fukushima N. ^{[1
]}

Sawa Y. ^{[1
]}

Masai T. ^{[1
]}

Kadoba K. ^{[1
]}

Kagisaki K. ^{[1
]}

Chang J.-C. ^{[1
]}

Yamaguchi T. ^{[1
]}

Matsuda H. ^{[1
]}

机构：

[1] First Department of Surgery, Osaka University Medical School, Suita, Osaka 565

来源：

Surgery Today | 1999年 / 29卷 / 3期

关键词：

Aortic cross- clamp; Beating-heart surgery; Cardiopulmonary bypass; Ultra-short-acting; β-blocker;

D O I：

10.1007/BF02483015

中图分类号：

学科分类号：

摘要：

The administration of an ultra-short-acting β-adrenergic antagonist, esmolol, has been introduced as a novel method for beating-heart surgery. In the present study, a new ultra-short-acting β-blocker, ONO-1101, was administered during cardiopulmonary bypass (CPB) to investigate its effects on cardiac function and hemodynamics. Nine adult mongrel dogs underwent 60 min of CPB during which they were given either ONO-1101 (ONO group; n = 4) or saline (control group; n = 5). In the ONO group, the hearts became flaccid enough for surgery to be performed without cardiac standstill within 10 min after the commencement of ONO-1101 with significant decreases in the heart rate, the preload recruitable stroke work (PRSW), and the slope of the end- systolic left ventricular pressure-volume relationship (E(max)). The mean arterial pressure and systemic vascular resistance also decreased, but were maintained above 50 mmHg during CPB without catecholamine. These indices increased to the control group level 20 min after the discontinuation of ONO- 1101. The serum concentration of ONO-1101 decreased from the maximum level of 121 ± 15 μg/ml soon after infusion to 11 ± 5 μg/ml within 30 min after discontinuation. These data suggest that ONO-1101 may be useful to enable beating-heart surgery to be performed without aortic cross-clamp as an ultra- short-acting β-adrenergic blocker.

引用

页码：248 / 254

页数：6

共 18 条

[1] Abramson D.C., Pivalizza E.G., Gottschalk L.I., Drug management for coronary revascularization without cardiac standstill: The use of high dose esmolol, J Cardiothorac Vasc Anesth, 9, pp. 184-188, (1995)
[2] Pirk J., Kellovsky P., An alternative to cardioplegia, Ann Thorac Surg, 60, pp. 464-465, (1995)
[3] Sweeney M.S., Frazier O.H., Device-supported myocardial revascularization: Safe help for sick hearts, Ann Thorac Surg, 54, pp. 1065-1070, (1992)
[4] Matsuda H., Fukushima N., Kadoba K., Sawa Y., Nomura F., Kume Y., Miyagawa S., Shimazaki Y., Application of ultra-short acting beta-blockade (Esmolol) in pediatric open heart surgery: A trial in total anomalous pulmonary venous return, J Cardiac Surg, 11, pp. 101-105, (1996)
[5] Pivalizza E.G., Sweeney M.S., High-dose esmolol and cardiopulmonary bypass for mitral valve replacement in the beating heart, J Cardiothorac Vasc Anesth Jun, 11, 4, pp. 485-486, (1997)
[6] Waldenberger F.R., Hotz H., Haisjackl M., Konertz W., Surgical coronary revascularization of the beating heart, Z Kardiol, 85, SUPPL. 4, pp. 35-41, (1996)
[7] Olearchyk A.S., Calcified ascending aorta and coronary artery disease, Ann Thorac Surg, 59, pp. 1013-1015, (1995)
[8] Takahashi T., Kadoba K., Taniguchi K., Sawa Y., Imagawa H., Masai T., Matsuda H., Repair of postinfarction ventricular septal defect on a beating heart, Ann Thorac Surg, 61, pp. 1816-1817, (1996)
[9] Muraki K., Nakagawa H., Nagano N., Henmi S., Kawasumi H., Nakanishi T., Imaizumi K., Tokuno T., Atsuki K., Imaizumi Y., Watanabe M., Effects of ono-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle, J Pharmacol Exp Ther, 278, 2, pp. 555-563, (1996)
[10] Sum C.Y., Yacobi A., Kartzinel R., Stampfli H., Davis C.S., Lai C.M., Kinetics of esmolol, an ultra-short-acting beta-blocker, and of its major metabolite, Clin Pharmacol Ther, 34, pp. 427-434, (1983)

← 1 2 →